Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice

Kenneth E. Kinnamon; Arba L. Ager; Robert W. Orchard

doi:10.1016/0014-4894(76)90070-9

Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice

Kenneth E. Kinnamon, Arba L. Ager, Robert W. Orchard

Microbiology & Immunology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The drugs 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline (WR 158,122)and its tetrahydro analog (WR 180,872) were found to act synergistically in reducing the parasitemia of Plasmodium berghei infected mice. Evidence was found that both the drugs which are potent folic acid antagonists were acting at different sites in the folic acid metabolic pathway, neither of which was at the action site of p-aminobenzoic acid (PABA)inhibitors. Advantages of drug combinations in malaria chemotherapy are discussed.

Original language	English (US)
Pages (from-to)	95-102
Number of pages	8
Journal	Experimental Parasitology
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/0014-4894(76)90070-9
State	Published - Aug 1976

Keywords

Antifols
Chemotherapy, malaria
Combined drug therapy
Dihydrofolate reductase inhibitors
Drug antagonism
Drug combinations
Drug synergism
Enzymes
Folic acid
Inhibitors, metabolic
Malaria
Metabolic inhibitors
Mice
Plasmodium berghei
p-Aminobenzoic acid

ASJC Scopus subject areas

Parasitology
Immunology
Infectious Diseases

Access to Document

10.1016/0014-4894(76)90070-9

Fingerprint Dive into the research topics of 'Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice'. Together they form a unique fingerprint.

Cite this

@article{480be90c44354e99bbc158ea87ed0c0a,

title = "Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice",

abstract = "The drugs 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline (WR 158,122)and its tetrahydro analog (WR 180,872) were found to act synergistically in reducing the parasitemia of Plasmodium berghei infected mice. Evidence was found that both the drugs which are potent folic acid antagonists were acting at different sites in the folic acid metabolic pathway, neither of which was at the action site of p-aminobenzoic acid (PABA)inhibitors. Advantages of drug combinations in malaria chemotherapy are discussed.",

keywords = "Antifols, Chemotherapy, malaria, Combined drug therapy, Dihydrofolate reductase inhibitors, Drug antagonism, Drug combinations, Drug synergism, Enzymes, Folic acid, Inhibitors, metabolic, Malaria, Metabolic inhibitors, Mice, Plasmodium berghei, p-Aminobenzoic acid",

author = "Kinnamon, {Kenneth E.} and Ager, {Arba L.} and Orchard, {Robert W.}",

year = "1976",

month = aug,

doi = "10.1016/0014-4894(76)90070-9",

language = "English (US)",

volume = "40",

pages = "95--102",

journal = "Experimental Parasitology",

issn = "0014-4894",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Plasmodium berghei

T2 - Combining folic acid antagonists for potentiation against malaria infections in mice

AU - Kinnamon, Kenneth E.

AU - Ager, Arba L.

AU - Orchard, Robert W.

PY - 1976/8

Y1 - 1976/8

N2 - The drugs 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline (WR 158,122)and its tetrahydro analog (WR 180,872) were found to act synergistically in reducing the parasitemia of Plasmodium berghei infected mice. Evidence was found that both the drugs which are potent folic acid antagonists were acting at different sites in the folic acid metabolic pathway, neither of which was at the action site of p-aminobenzoic acid (PABA)inhibitors. Advantages of drug combinations in malaria chemotherapy are discussed.

AB - The drugs 2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline (WR 158,122)and its tetrahydro analog (WR 180,872) were found to act synergistically in reducing the parasitemia of Plasmodium berghei infected mice. Evidence was found that both the drugs which are potent folic acid antagonists were acting at different sites in the folic acid metabolic pathway, neither of which was at the action site of p-aminobenzoic acid (PABA)inhibitors. Advantages of drug combinations in malaria chemotherapy are discussed.

KW - Antifols

KW - Chemotherapy, malaria

KW - Combined drug therapy

KW - Dihydrofolate reductase inhibitors

KW - Drug antagonism

KW - Drug combinations

KW - Drug synergism

KW - Enzymes

KW - Folic acid

KW - Inhibitors, metabolic

KW - Malaria

KW - Metabolic inhibitors

KW - Mice

KW - Plasmodium berghei

KW - p-Aminobenzoic acid

UR - http://www.scopus.com/inward/record.url?scp=0017097925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017097925&partnerID=8YFLogxK

U2 - 10.1016/0014-4894(76)90070-9

DO - 10.1016/0014-4894(76)90070-9

M3 - Article

C2 - 780121

AN - SCOPUS:0017097925

VL - 40

SP - 95

EP - 102

JO - Experimental Parasitology

JF - Experimental Parasitology

SN - 0014-4894

IS - 1

ER -

Plasmodium berghei: Combining folic acid antagonists for potentiation against malaria infections in mice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this